Entity

Time filter

Source Type

Shanxi, China

Wang J.-L.,Shanxi Cancer Hospital
Cancer Research and Clinic | Year: 2013

Objective: To evaluate the efficacy and safety of sunitinib as first line treatment in patients with metastatic renal cell carcinoma (mRCC). Methods: A total of 40 patients with mRCC were treated with sunitinib between January 2009 and December 2011, including 27 males and 13 females. The median age was 59 (31-75) years old. All patients received a pathologic diagnosis of renal clear cell carcinomas with radical nephrectomy. All cases were treated with first line therapy. Sunitinib monotherapy was administered in repeated 6-week cycles of daily oral therapy for 4 weeks, followed by 2 weeks off in 34 patients,while another 6 patients received 37.5 mg/d continuously until disease progression or unacceptable toxicities occurred. Overall response rate and safety were evaluated. Results: The median follow up was 14 months (range 4-36 months). All patients could be evaluated the efficacy. 17.5 % (7/40) patients achieved partial responses, 77.5 % (31/40) atients were in stable and 2 (5.0 %) patients were with disease progression including 1 death. The objective response rate was 17.5 % (7/40), and the disease control rate was 95.0 % (38/40). The most common side effects included fatigue 12 cases (30.0 %), alopecia 3 cases (7.5 %), thrombocytopenia 23 cases (57.5 %), thyroid dysfunction 26 cases (65.0 %), neutropenia 20 cases (50.0 %), hypertension 18 cases (45.0 %), hand-foot syndrome 17 cases (42.5 %) and diarrhea 4 cases (10.0 %). The major grade 3 adverse events included thrombocytopenia 2 cases (5.0 %) and edema 1 case (2.5 %). Most adverse events were ameliorated by treatment interruption. Conclusion: Sunitinib has definitive efficacy for patients with mRCC with slight side effects. Source


Yongfeng G.,Shanxi Cancer Hospital
Cancer Research and Clinic | Year: 2014

Objective: To evaluate the significance of suPAR, SCC-Ag in plasma and HPV16, 18 in cervical secretion for monitoring pathogenetic condition and prognosis in patients with cervical cancer. Methods: 206 cervical cancer patients' blood and cervical secretion were collected. Plasma level of suPAR and SCC-Ag were measured by enzyme linked immunosorbent assay (ELISA) in health women and patients with cervical cancer. The expression of HPV16, 18 of cervical secretion in control group and patients with cervical cancer were detected by fluorescence quantitative PCR. The correlations of the three indexes were analyzed. Results: The plasma level of suPAR and SCC-Ag, the expression of HPV16, 18 of cervical secretion in cervical cancer patients were obviously higher than those in health controls with statistical significance ((1.072 5±0.305 2) ng/ml vs (0.501 7±0.179 3) ng/ml, (0.980 6±0.162 7) μg/ml vs (0.261 4±0.006 3) μg/ml and 53.89 % (90/167), 46.15 % (18/39) vs 6.67 % (4/60), P < 0.05). There was a positive correlation between plasma suPAR level and SCC-Ag level in invasive carcinoma of cervix patients (r = 0.564, P < 0.05). The plasma level of suPAR between in HPV16, 18 positive group and in HPV16, 18 negative group did not show difference (P > 0.05). Conclusions: In invasive carcinoma of cervix patients, there is a positive correlation between plasma suPAR level and SCC-Ag level. But it's not yet to conclude that plasma suPAR level of cervix invasive carcinoma patients is related to infection of HPV16, 18. Source


Shuangping Z.,Shanxi Cancer Hospital
Cancer Research and Clinic | Year: 2014

Objective: To investigate the diagnostic value of combined examination of homocysteine (Hcy) and CEA for male patients with gastric cardia cancer. Methods: Serum concentration of Hcy, CEA, CA199, CA724, CA242 and TPS in 54 male patients with gastric cardia cancer and in 30 healthy men were measured. The diagnostic efficacy was analyzed between the combination of Hcy, CEA and the combination of Hcy, CEA, CA199, CA724, CA242, TPS. Results: Total Hcy, CEA levels were significantly increased in patients group compared with control group ((20.3±9.2) μmol/L vs (13.7±3.1) μmol/L, (7.8±3.5) μg/L vs (1.6±1.2) μg/L, P < 0.05). The sensitivity, specificity and accuracy of the combination of CEA, CA199, CA724, CA242 and TPS were 73.6 %, 64.5 % and 70.2 % respectively, while those of the combination of Hcy, CEA were 92.5 %, 64.5 % and 82.1 %, respectively. There was significant difference between the combination of Hcy, CEA and the combination of CEA, CA199, CA724, CA242 and TPS (P < 0.05). Conclusion: Combined detection of Hcy and CEA is helpful for diagnosis in male patients with gastric cardia cancer. Source


Zhang S.,Shanxi Cancer Hospital
Cancer Research and Clinic | Year: 2014

Objective: To evaluate the changes and clinical significance of the serum levels of homocysteine (Hcy) in gastric cardia cancer patients before and after surgery. Methods: Serum Hcy concentrations of 102 patients with gastric cardia cancer (including 69 case of males) and 50 healthy human were measured by enzymatic cycling assay. Results: Total Hcy levels were significantly increased in male patient group compared with the levels in control group (t = 5.143, P = 0.001). Hcy levels were significantly lower in postoperative group compared with preoperative group [(17.08±5.31) μmol/L vs (20.34±9.26) μmol/L, (14.07±4.87) μmol/L vs (20.34±9.26) μmol/L, P < 0.05]. Compared with IV stage group and other TNM stage groups, significantly lower levels of Hcy were detected in patients with gastric cardia cancer (t = 2.306, 3.285, P = 0.030, 0.002). Hcy levels in patients with gastric cardia cancer were also significantly higher than those in the tumor length < 3 cm, 3-5 cm and > 5 cm groups (t = 2.461, 2.147, P = 0.017, 0.038). Multiple logistic regression analysis indicated a statistically significant association between serum Hcy concentration and gastric cardia cancer incidence (OR = 1.136, 95% CI 1.010-1.278, P= 0.033). Increasing serum Hcy levels were significantly associated with a decreasing risk of metastatic lymph node (OR = 0.865, P = 0.010). Conclusion: Serum Hcy levels are directly associated with risk of male patients with gastric cardia cancer, and play important roles in the development of gastric cardia cancer. Source


Song X.,Shanxi Cancer Hospital
Cancer Research and Clinic | Year: 2015

Objective To investigate the clinical characteristics, the principles of diagnosis, treatment and the prognosis of primary esophageal cancer. Methods 53 patients with esophageal cancer were analyzed, including in 28 cases of synchronous carcinoma (SC) and 25 cases of metachronous carcinoma (MC). 8 patients received simple operation without following chemotherapy, 28 patients with esophageal and stomach lesion were treated by operation and radiation and chemotherapy, and only 17 patients were treated with simple chemotherapy. Total cases were followed up for survival time. Results The 1-, 3- and 5-year survival rates were 64.3 % (18/28), 7.1 % (2/28), 7.1 % (2/28) in SC, and were 100.0 % (25/25), 80.0 % (20/25), 40.0 % (10/25) in MC (P< 0.05). For different treatments, the 1-, 3- and 5-year survival rates were 75.0 % (6/8), 25.0 % (2/8), 25.0 % (2/8) in simple operation, 52.9 % (9/17), 0, 0 in simple chemoradiotherapy, and 100.0 % (28/28), 71.4 % (20/28), 35.7 % (10/28) in operation plus chemoradiotherapy. The results from multiple factors regression analysis showed that the pathogenesis, pathological type, the time interval of onset were the independent prognostic factors which can influence the survival time (chi square values were 1.330, 0.023, 0.056, all P < 0.05). Conclusions MC patients have longer survival time and higher survival rate than SC patients. There is no difference of the 1-, 3-, 5-year survival rates of patients with different treatments. Source

Discover hidden collaborations